BiotechTube

Roflumilast Foam 0.3% + Vehicle Foam

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scalp Psoriasis

Conditions

Scalp Psoriasis

Trial Timeline

Aug 24, 2021 → Jun 3, 2022

NCT ID
NCT05028582

About Roflumilast Foam 0.3% + Vehicle Foam

Roflumilast Foam 0.3% + Vehicle Foam is a phase 3 stage product being developed by Arcutis Biotherapeutics for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05028582. Target conditions include Scalp Psoriasis.

What happened to similar drugs?

0 of 5 similar drugs in Scalp Psoriasis were approved

Approved (0) Terminated (0) Active (5)
🔄PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
🔄DSXS + PlaceboSun PharmaceuticalPhase 3
🔄DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
🔄Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
🔄Secukinumab 300 mg + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT05028582Phase 3Completed
NCT04128007Phase 2Completed
NCT04091646Phase 2Completed

Competing Products

7 competing products in Scalp Psoriasis

See all competitors
ProductCompanyStageHype Score
DSXS topical productSun PharmaceuticalPhase 2
35
PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
40
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
40
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspensionSun PharmaceuticalPhase 1
29
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
40
Secukinumab 300 mg + PlaceboNovartisPhase 3
40